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Abstract
Obesity can affect the pharmacokinetics of most drugs, which may result in under-
or overdosing if traditional pediatric dosing strategies are used. To investigate cur-
rently applied dosage strategies in children with overweight or obesity (overweight/
obesity), in a clinical treatment facility. In particular, whether dosing guidelines were
available and metrics of body size applied. A retrospective cohort study of 200
patients admitted to the Danish Children0s Obesity Clinic. Data were collected from
2007 to 2015. Overweight/obese children 3-18 years were included if they had at
least one drug prescription. Overall there were 658 prescriptions, primarily anal-
gesics, psychotropics, asthma medications, and antibiotics. Except for one prescrip-
tion, guidelines for dosage of overweight/obese children were not available in the
clinic. In one prescription of gentamicin, the dose was adjusted by a metric body
size. Otherwise dose was predominately prescribed either by total body weight or
as fixed dose by age, in accordance with the recommendations of normal weight
children. In drugs with a narrow therapeutic interval, we found large interindividual
variations in dosing regimens, that is, for gentamicin, paracetamol, and prednisolone.
Reduction of dose to the maximum recommended adult dose was common practice,
when the dose calculated by total body weight (ie, mg/kg) exceeded this maximum.
This study highlights the shortage of dosing guidelines in overweight/obese children.
We found a large interindividual variability in dosage regimens, even in drugs with
narrow therapeutic intervals. The clinicians rely on “best practice”, as evidence-
based dosage regimens are missing for many drugs prescribed during childhood.
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childhood obesity, clinical pharmacology, dosing regimens, overweight, pediatrics
1 | INTRODUCTION
Obesity is associated with a wide range of serious health complica-
tions, including asthma, musculoskeletal disorders, depression, sleep
apnea, dyslipidemia, hypertension, steatosis, diabetes type 2, and
Abbreviations: ABW, adjusted body weight; ATC, anatomical therapeutic chemical; BMI,
body mass index; CL, clearance; IBW, ideal body weight; LBW, lean body weight.
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numerous cancers.1,2 Consequently, children who are overweight
and obese are more likely to receive drug treatment than their nor-
mal weight peers.3,4
1.1 | Drug dosing in normal weight children and
challenges in overweight/obese children
One of the most common methods for drug dosing in children in
pediatric clinical practice is to extrapolate adult dose by body weight,
eg mg per kilogram (kg).5 This approach represents an a priori
assumption of a linear relationship between weight and dose, as dose
doubles with a twofold increase in the weight of a child.5 Another
common method for dosing in children is based on age, by dividing
the pediatric population into subcategories of age. This method intro-
duces an artificial discontinuity in the dose-response relationship
across each age category.5As a result of the high weight relative to
height in children with overweight/obese, a linear dosing by total
body weight (TBW) might even exceed the maximum recommended
dose in adults, while fixed dosage by age may result in subtherapeutic
doses.5 In addition, the principal pharmacokinetic (PK) determinants
of drug dosing, that is, volume of distribution (Vd) and clearance (CL)
are both often altered in obese patients. This is partly due to changes
in physiology and body composition, with a relatively higher increase
in fat (60%) compared to lean tissue (40%) per kg of TBW, as well as
lean mass is more hydrated, which is attributed to increased extracel-
lular water.6 In addition, alterations in drug binding proteins, cardiac
output, organ blood flows, and tissue perfusion may influence the
PK.7,8 Even though, the hepatic metabolism and the influence of obe-
sity in children not has been studied extensively.8 Further, PK data in
this subgroup is not required for approval of new drugs by default by
the Danish health authorities or the European Medicine Agency
(EMA). The lack of clinical trials in children, who are overweight/
obese therefore prompts clinicians to extrapolate dosing strategies
from studies in adults with overweight. However, such extrapolation
strategies ignore differences in drug disposition (distribution and
elimination) characteristics, reflecting children’s general degree of
immature metabolic pathways and physiological development. In
addition, pathophysiological alterations accompanying obesity are
assumed to have a similar influence on PK parameters in children,
who are overweight/obese as in adults.5,6,9,10 Ideal body weight
(IBW), lean body weight (LBW), adjusted body weight (ABW) and
allometric scaling, see Table 1. Whether the metrics are actually used
in clinical practice is uncertain.
1.2 | Objectives
To investigate currently applied dosing strategies in children, who are
overweight/obese, in a clinical treatment facility. In particular, whether
dosing guidelines were available and metrics of body size applied.
2 | MATERIALS AND METHODS
2.1 | Design and setting
A retrospective cohort study was conducted at the Children0s Obe-
sity Clinic, Department of Paediatrics, Holbaek University Hospital in
Region Zealand, in the period 2007-2015. The study was approved
by the Data Protection Agency (BBH-2014-045, I-suite 03045).
2.2 | Study participants
Two hundred consecutively enrolled overweight/obese children aged
3-18 years, entering the chronic care multidisciplinary intervention
program at the Children0s Obesity Clinic. Only children treated with at
least one drug were included. Children had been referred from their
general practitioners (GPs), school- and community-based doctors, or
pediatricians. Exclusion criteria were a Body Mass Index (BMI) Stan-
dard Deviation Score (SDS) ≤ 1.28, which corresponds to the 90th
percentile according to the Danish age and sex-adjusted references.11
2.3 | Data collection
Data collected comprised patient demographics including: date of
birth, gender, comorbidity, height, weight, and all drug prescriptions
from Department of Paediatrics or Division of Child and Adolescent
Psychiatry at entering day and during the follow up period. Data col-
lection was performed by a medical doctor from Department of Clin-
ical Pharmacology, Copenhagen.
2.4 | Outcomes and measures
The following data were collected for each specific drug: Indication
for treatment according to the International Classification of Dis-
eases version 10 (ICD-10),12 drug dose (milligram), dosage interval,
duration of treatment, age of child at prescription time (years),
weight (kg), and height (cm). For evaluating dosage strategies, the
following data were registered: dosage by total body weight (TBW),
fixed dose by age (years), use of adjusted weight measures (eg LBW,
TABLE 1 Metrics of body size, used to calculate dose in children
with overweight/obese
Metrics of
body size Formula
TBW, kg Total body weight
LBW, kg Male: (1.1 9 TBW)–(0.0128 9 BMI 9 TBW)
Female: (1.07 9 TBW)–(0.0148 9 BMI 9 TBW)
IBW, kg BMI 50th percentile for age and gender (children)
ABW, kg IBW + (0.4 9 (TBW–IBW)
BSA, m2 TBW 9 0.024265 9 height (cm)0.3964 9 TBW
(kg) 0.5378 or (TBW 9 height (cm)/3.600)½
Allometric
scaling
CL child = CLadult(TBWchild/70)b
b = the allometric coefficient for CL, usually
set at 0.75.
Oral dose in steady state (ss) is then:
Doseoral = Cav,ss 9 CL 9 Ϯ/F
LBW, lean body weight; ABW, adjusted body weight; BMI, body mass
index; IBW, ideal body weight; BSA, body surface area; Cav, average
plasma concentration in steady state; Ϯ, dose interval; F, bioavailability.
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BSA, IBW, ABW) or dose estimation by other strategies. If available,
specific drug dosing guidelines for overweight/obese children would
be used as reference document; Guidelines for each drug prescribed
were searched in the local pediatric treatment facility, herein the
electronic prescription system; “Opus Medicine”. Furthermore, at the
official Danish Websites: Pro.medicin.dk, The Danish Society of Pae-
diatricians0 http://www.paediatri.dk, and the Summary of Product
Characteristics (SmPC).
For standardization, the WHO Anatomical Therapeutic Chemical
(ATC) Classification System for medication was used. WHO-ATC uses
a hierarchical system for classifying medicines into distinct groups at
five levels according to the organ or system on which they act and
their chemical, pharmacological and therapeutic properties. Dosing
strategy was determined by simple backwards calculation of total dose
(eg in mg per kg) and with concordance to the available dosing guide-
lines. Dosing strategies found were discussed continuously with a
group of senior MDs in Clinical Pharmacology and—Pediatrics.
2.5 | Statistical analysis
Continuous variables are presented as number of observations (per-
centages) or median (range), while categorical (nominal) variables are
presented, using number of observations or frequencies as
percentages. Data management was conducted, using R, version
3.2.2. The age of the child at first visit was stratified into two
groups: 2-11, 12-18 years according to the International Conference
on Harmonization’s, ICH-11 criteria.13
3 | RESULTS
Demographic characteristics are summarized in Table 2. In total,
1372 patient records and medication charts were reviewed in order
to achieve the predefined sample of 200 patient records comprising
at least 1 prescription in the study period. The cohort included 63%
females, almost equally divided into the two subpopulations of 3-
11 years (48%) and 12-18 years (52%), respectively. In males, the 3-
11 years old constitute the largest group (62%).
Distribution of all drug prescriptions in accordance to the ATC
classification system is illustrated in Figure 1. Totally 658 prescrip-
tions were registered, of these were 203 registered at the first visit.
A majority of the prescriptions (46%) were respiratory drugs (ATC
group R), followed by drugs acting on the nervous system (ATC
group N; 27%) , for example, central nervous system stimulants and
analgesics, and drugs acting on the alimentary tract and metabolism
(ATC group A; 9%), mainly laxative drugs and proton pump
TABLE 2 Demographic characteristics at the first visit to The clinic of obese children
Characteristics Total 2-11 years 12-18 years
N (%) 200 107 (53.5) 93 (46.5)
Age, years (median, range) 11 (3-18) 10 (3-11) 14, 5 (12-18)
Male (%) 126 (63) 60 (48) 66 (52)
Female (%) 74 (37) 46 (62) 28 (38)
BMI z-score (median, range) 2.95 (1.28-9.72) 2.98 (1.64-9.72) 2.92 (1.28-7.78)
Distribution of co-morbidities, ICD-10-code and diagnosis: (%) 105 (100)a 56 (53) 49 (47)
D44.4-D69.3 Craniophanygioma, Autoimmune hemolytic anemia 3 1 2
E03.9-E.70 Myxoedama, Autoimmune thyroiditis, Type 1 diabetes,
Type 2 Diabetes Mellitus, Polycystic ovarian syndrome, Precocious
puberty, Endocrine disorder, unspecified, Disorders of aromatic amino-acid metabolism
12 5 7
F32-F99.2 Depressive episode, Other anxiety disorders,
Borderline personality, Infantile autism, Asperger syndrome,
Attention-deficit hyperactive disorder, Tourette disorder
19 6 13
G40 Epilepsy 4 3 1
I10 Hypertension 2 1 1
J45 Asthma 43 30 13
K21-59 Gastroesophageal reflux disease, Constipation 7 3 4
L20-L40 Atopic dermatitis, Psoriasis 4 2 2
M00-M99 Musculoskeletal disorders, Low back pain 3 1 2
Q14-Q89.3 Congenital malformations of posterior segment of eye,
Other congenital malformations of male genital organs, Other congenital
musculoskeletal deformities, Bardet-Biedl syndrome, Dextrocardia with situs in versus
5 3 2
R32 Unspecified urinary incontinence 1 0 1
T78.4 Allergy, unspecified 2 1 1
ICD, international classification of diseases.
Data are presented as median (range) or frequencies in numbers or percent.
aSome of the patients are represented in more than one group.
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inhibitors. The remaining 18% were distributed between various
groups. In the follow-up period, during hospitalization, a total num-
ber of 455 prescriptions were registered, primarily within the ATC
groups as registered at the primary visit (groups N, A & R), in addi-
tion to antibiotics (ATC group J). In accordance with these prescrip-
tion patterns, the majority of comorbidities comprised of 41% (43/
105) asthma diagnoses (ICD-10 code J45), while 22% had a mental
—and behavioral disorder (codes F32 to F99.2) or disorders of the
nervous system (code G40),Table 2. Eleven percent had an ICD-code
of endocrine, nutritional and/or metabolic disorder (codes E03.9 to
E.70) and 7% had a disorder of the digestive system (codes K21 to
K59). The remaining 19% was widely distributed between various
comorbidities.
3.1 | Dosing strategies
Distribution of the individual drugs prescribed at ATC-level five, and
the dose regimen used in the follow up period is presented in
Table 3. Drugs were prescribes approximately fifty-fifty as fixed
dose by age (N = 183) or by TBW (N = 179), and in accordance with
the SmPCs.
Specific guidelines for dosing strategies in children with over-
weight/obese were not available for any of the drugs prescribed.
Neither at the Children’s obesity clinic, or at the official website of
The Danish Society of Paediatricians, which contains various national
pediatric dosing guidelines,14 nor were there any supportive dosing
parameters incorporated in the electronic system; “Opus Medicine”.
Further, The Danish Website: pro.medicin.dk15 only provides pre-
scription guidelines for gentamicin for obese adults. The metric used
for body size is adjusted by weight (ABW).
In the ATC group J (antibiotics), gentamicin was prescribed in 4 of
200 patients, which comprised in total 6 prescriptions. They were
dosed after three different dosage regimens, either by TBW, ABW,
or dose-capping. Toxicity was not reported and Therapeutic Drug
Monitoring (TDM) was performed in all cases. Phenoxy-methyl peni-
cillin was prescribed as a fixed dose in accordance with adult regi-
men in the majority of the children, as a dose of 1.000.000 IE three
times per day. In only one patient, the dose was calculated by TBW
in accordance to the SmPC, whereas both Benzyl-penicillin (i.v) and
Ampicillin (i.v.) were dosed by TBW, Table 2.
Systemic use of prednisolone (ATC group H) were registered in
totally 10 cases, prescribed by various doses depending on indica-
tion, which were allergic reaction, angioedema, asthma and autoim-
mune hemolytic anemia, median dose 25 mg/day (range 2.5-50 mg/
day). Methylprednisolone was prescribed in three cases also with
dose primarily depending on indications, which were asthma, allergic
reaction, and colitis ulcerosa, median dose was 40 mg/day (range
40-80 mg/day).
For the ATC group M, which comprises nonsteroidal anti-inflam-
matory drugs, ibuprofen was prescribed as a fixed dose of 400 mg
three times/day in the majority of prescriptions, whereas diclofenac
was dosed as 50 mg three time per day in 5 of 7 prescriptions and as
150 mg three times per day, and at last as 100 mg as a single dose.
For ATC group N: In total, 34 prescriptions of paracetamol were
registered. In 15 cases, paracetamol was dosed by TBW in accor-
dance with a normal weight children dosing regimen and in 9 cases
dose-capping was registered when dose exceeded the recommended
maximum adult dose and in 3 cases dose prescribed exceeded the
dose calculated by TBW. In one case, the recommended maximum
adult dose was exceeded. In total, 7 prescriptions of morphine were
registered, of these 5 were prescribed as subcutaneous administra-
tions, dosed by TBW in accordance to the SmPC, and 2 prescriptions
were administered as tablets, both as 5 mg per dose, which in both
cases was lower than the recommended initial dose for normal
weight children. Only 2 prescription of diazepam was registered as a
dose of 10 mg, which is the maximum recommended dose for treat-
ment of seizures in children in general, and in accordance to the rec-
ommendations at The Danish Society of Paediatricians official
website.14 Further, 4 prescriptions of lamotrigine were registered all
prescribed as fixed dose by age during maintenance treatment of
epilepsy.
For ATC group R: 32 registrations of asthma medications were
registered, herein inhaled beta-2 agonists, inhaled corticosteroids,
fixed dose combination, and montelukast. All drugs in group R were
prescribed as fixed dose by age.
4 | DISCUSSION
This study gives an overview of clinical practice in dosing of over-
weight/obese children in different pediatric settings. We found no
specific dosing guidelines available for overweight/obese children in
the investigated clinics for any of the recorded drugs. As limited data
are available in overweight/obese children for most drugs, the
results of this study will most likely apply to other pediatric settings
in Denmark as well as internationally.
4.1 | Antibiotics
In line with other studies,16,17 we found a noticeable prescription of
antibiotics (ATC group J), of which, it is well known that in addition
to therapeutic failure, inappropriate dosage can lead to antibiotic
resistance, and drug-related toxicity. Nonetheless, we found only
one overweight/obese child dosed by an adjusted metric of body
size, which was gentamicin dosed by ABW in treatment of
pyelonephritis. It is generally accepted that the initial empiric dose
(loading-dose) is critical to achieve an early high peak concentration
of gentamicin that directly correlates with maximal killing of the
pathogen.18 One PK study of gentamicin has been performed in
overweight/obese children,18 and based on the results, it has been
suggested that the total daily dose per kilogram bodyweight should
be based on ABW, similar to adults.18,19 Nonetheless, we found
three other overweight/obese children, who had gentamicin pre-
scribed by other and different dosing strategies. Herein, a 18-year-
old female with a weight of 106 kg, height 169.3 cm, who received
a loading dose of 240 mg gentamicin prescribed in the treatment of
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TABLE 3 Distributionen on individual drugs at ATC-level five and the dose regimen used. Each patient can be represented in more than
one group
Drug (ATC-code, Genericum)
Number of
prescriptions
N:455
Fixed dose
by age
N:183
Dosed per total
kilogram body weight
N: 179
Dose estimation
N:28
Age (median,
range)
A10BA02, insuline detemir 1 — — — 10
A02AA04, magnesium oxide 1 — — — 16
A02BC01, omeprazole 4 4 — — 13 (10-16)
A02BC02, pantoprazol 3 3 — — 17 (13-18)
A02BC03, lansoprazole 4 3 — — 17 (13-18)
A02BC05, esomeprazole 1 1 — — 18
A02BX13,gaviscon 1 1 — — 16
A06AB08,sodium picosulfate 2 2 — — 15.5 (15-16)
A06AD11, lactulose 1 1 — — 10
A06AD65, Movicol 12 12 — — 12 (4-16)
A07EC02, mesalazine 4 4 — — 16 (13-16)
A08AB01, orlistat 2 — — — 13
A10BA02, metformin 1 1 — — 17
A10AB05, aspartat1 1 — — — 10
A11CC05, cholecalciferol 1 1 — — 16
B01AA03, warfarin 1 1 — 1 18
B01AB04, dalteparin 1 — 1 1 18
B02AA02, tranexamic acid 1 — 1 — 17
B03BB01, folic acid 1 — — 1 14
B03AA02,ferrous fumerat/vitamin C2 1 — — — 13
B03AA07,ferrous sulfate 1 — — — 16
C07AA05, propranolol 1 1 — 1 15
C03CA01, furosemide 1 — 1 1 13
C08CA01, amlodipine 1 1 — — 13
C09AA01, captopril 2 — 1 1 16
D07AB02, hydrocortisone butyrate 1 — — — 10
D07AD01, clobetasolpropionat 1 1 — — 11
D10AE51, benzoyl peroxide, clindamycin 1 1 — — 13
G03AA07, COC3, 2.generation progestin 7 — — — 17 (15-17)
G03AC01, norethisteron, 1.generation 1 — — — 17
G03AC09, desogestrel, 3.generation 2 — — — 17 (16-18)
G03DA02, medroxyprogesteronacetate 1 — 1 — 15
G04BD08, solifenacin 2 — — — 15.5 (11-16)
H01BA02, desmopressin 1 1 — — 8
H02AB02, dexamethason 1 — — — 12
H02AB04, methylprednisolone 3 — 3 2 16 (15-16)
J01CA01, ampicillin 3 — 3 — 6 (5-17)
J01CA08, pivmecillinam 4 — 4 2 13 (5-15)
H02AB06, prednisolone 10 2 3 2 17 (10-18)
J01CA04, amoxicillin 2 2 — — 5
J01DC02, cefuroxime 2 1 1 — 16 (14-18)
J01CE01, benzylpenicillin 3 — 3 — 11 (10-17)
J01CE02, phenoxymethylpenicillin 8 — 1 — 13.5 (6-17)
(Continues)
GADE ET AL. | 5 of 10
TABLE 3 (Continued)
Drug (ATC-code, Genericum)
Number of
prescriptions
N:455
Fixed dose
by age
N:183
Dosed per total
kilogram body weight
N: 179
Dose estimation
N:28
Age (median,
range)
J01CF01, dicloxacillin 5 — 3 — 11 (11-13)
J01DH02, meropenem 1 1 — — 16
J01EE01, sulfametoxazol/trimetoprim 1 1 — — 17
J01FA09, chlarithromycin 2 — — — 18
J01FA10, azithromycin 4 4 — — 16.5 (11-18)
J01GB03, gentamicin 6 — 5 2 5 (5-18)
J01MA02,ciprofloxacin 4 2 2 1 16.5 (16-18)
J01XE01, nitrofurantoin 2 1 — — 11.5 (7-16)
J05AB01, acyclovir 1 — — — 11
L02AE02, leoprorelin 2 — — — 13
L04AB02, Infliximab 1 — — — 16
M01AE01, ibuprofen 11 11 — — 13 (11-18)
M01AE02, naproxen 1 1 — — 18
M01AB05, diclofenac 7 — — — 15 (6-17)
M03BB03, chlorzoxazone 1 1 — — 18
N02AA01, morphine 7 1 6 14 (13-18)
N02AX02, tramadol 2 2 — — 17, 5 (17-18)
N02BE01, paracetamol 34 2 15 9 13 (5-18)
N05AF03, chlorprothixen 12 1 — — 14 (13-18)
N05AH03, olanzapine 1 — — — 14
N05AH04, quetiapine 15 — — — 14 (10-18)
N05AX08, risperidone 2 2 — — 10
N03AX09, lamotrigene 4 4 — — 14
N05AX12, aripiprazole 15 4 — — 13.5 (10-16)
N05BA01, diazepam 2 2 — — 12 (11-13)
N05BA04, oxazepam 1 1 — — 18
N05CF01, zopiclone 1 — — — 16
N05CH01, melatonin 12 — — — 13.5 (8-15)
N06AB03, fluoxetine 6 6 — — 15.5 (11-16)
N06AB04, citalopram 6 1 — — 11 (10-18)
N06AB06, sertraline 15 5 — — 15 (11-16)
N06AX11, mirtazapine 2 — — — 17
N06AX16, venlafaxine 1 — — — 17
N06BA04, methylphenidate 109 43 62 4 11 (4-17)
N06BA09, atomoxetine 12 — 12 - 13.5 (10-17)
N06BA12, lisdexamfetamine 6 6 — — 16 (15-16)
R03DC03, montelukast 4 4 — — 11.5 (6-15)
R06AD02, promethazine 3 3 — — 13 (11-17)
R03AC02, salbutamol 7 7 — — 13 (6-17)
R03AC03, terbutaline 7 7 — — 12 (9-15)
R03BA02, budesonide 8 8 — — 11 (9-18)
R03BA05, fluticasone propionate 3 3 — — 10 (6-12)
R01AD12, fluticasone furoate 2 2 — — 12.5 (11-14)
R06AA04, clemastine 1 1 — — 16
(Continues)
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pneumonia. The dose prescribed was 39% (152 mg) lower than the
dose calculated by ABW (392 mg). Opposite, a 5-year-old female
with a weight of 29.6 kg, height 106.4 cm, received a loading dose
of 180 mg, dosed by TBW (6 mg kg1). The dose prescribed was
60% (67.5 mg) higher than the ABW-based dose of 112.5 mg.
Despite their widespread use, there is very little information
regarding dosing penicillin in obese patients.20 We found phenoxy-
methyl penicillin prescribed as a fixed dose in accordance with adult
regimen in 7 out of 8 children. Consequently, a 6-year-old child had
an approximately fourfold higher daily dose per kg body weight, than
the 17-year adolescent (88 mg kg1 day1 vs 21 mg kg1 day1).
For penicillin’s in which time of the drug concentration above the
minimum inhibitory concentration (T > MIC) is important, it follows
that increasing doses or frequency will improve the PD. Further-
more, the therapeutic index for penicillin’s is wide, and it therefore
seems reasonable to dose penicillin by TBW in overweight/obese
children. However, this has to be investigated further, and PKPD
studies of penicillin in children, who are overweight/obese are there-
fore in demand.16,20
4.2 | Analgesics
We found a large interindividual dosing of paracetamol, and the cap-
ping dose was common practice. In a recent study by Rongen
et al.,21 the pharmacokinetics of paracetamol in morbidly obese adult
patients was investigated, with a specific emphasis on Cytochrome
(CYP) 2E1 mediated CL. Paracetamol plasma concentrations were
significantly lower in obese patients. Thus, an increased dose of
paracetamol may be anticipated to achieve a better pharmacody-
namic response in obese patients. However, the induced CYP2E1-
activity may also worsen the safety profile of paracetamol due to
higher concentrations of the toxic metabolite N-acetyl-p-benzoqui-
none (NAPQI). As paracetamol is the most prescribed drug in pedi-
atric wards internationally,22 PKPD studies in overweight/obese
children is of outmost importance to clarify this question.
4.2.1 | Ibuprofen
We found ibuprofen primarily prescribed as a fixed dose of 400 mg.
Reduced peak, increased Vd has been found for ibuprofen in adults
with obesity,23 indicating dose may have to be increased. Ibuprofen
has not been investigated in children overweight/obese. Due to
common severe adverse effects such as gastrointestinal bleeding;
increasing dose by extrapolation of adult data cannot be recom-
mended as standard in this population, without prior investigations.
4.2.2 | Medication for obstructive airways
We found that all the registered drugs in asthma treatment were
prescribed as fixed dose by age. Lower therapeutic responsiveness
TABLE 3 (Continued)
Drug (ATC-code, Genericum)
Number of
prescriptions
N:455
Fixed dose
by age
N:183
Dosed per total
kilogram body weight
N: 179
Dose estimation
N:28
Age (median,
range)
R06AE07, cetirizine 2 2 — — 13.5 (10-17)
V03AB23, acetylcysteine 1 — 1 — 16
Off label use (Indication, age, dose, form and dose interval) has not been specified in the table. Some drugs are not dosed by weight or age, that is, insu-
lin detemir, which is dosed by blood glucose level. For drugs prescribed off label or off license, it was not possible to specify dose regimen. Dose esti-
mation comprises dose capping and use of metrics of body size. The later only registered in one case, which was gentamicin dosed by ABW, with
reference to the Danish website www.promedicin.dk.
0 50 100 150 200 250 300 350
R
N
M
L
J
H
G
D
C
B
A
N = prescriptions
AT
C
F IGURE 1 Distribution of prescriptions
registered at first visit and distribution of
prescriptions conducted during
hospitalization. In total: N = 658
prescriptions. Light green color bar chart:
203 prescriptions registered at the first
visit. Dark green color bar: 455
prescriptions registered during
hospitalization. Some of the children are
represented in more than one ATC group
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has been shown in overweight vs nonobese children; in one study
by measuring b-agonist units dispensed per year and oral corticos-
teroid dispensing,24 and in other studies as response to inhaled
corticosteroid.25-27
4.2.3 | Antiepileptic drugs
We found one and four prescriptions of diazepam and lamotrigine,
respectively. Both antiepileptic drugs are widely used in pediatric
patients. Diazepam is a highly lipophilic drug, which has been found
to have an increased Vd in obese adult patients.
28 As Vd is the pri-
mary PK parameter of importance when calculating loading dose, the
initial dose may have to be increased in overweight/obese children.
Opposite, lamotrigine is used for maintenance treatment of epilepsy.
CL is therefore the primary PK parameter of importance when dos-
ing. However, the effect of obesity on lamotrigine PK has not been
investigated.
The lack of sufficient data on how to dose children who are
overweight and or obese in acute care, such as antibiotics, anti-epi-
leptics, and drugs with narrow therapeutic interval, that is, gentam-
icin, paracetamol, and diazapam is concerning.
In the light of the prevalence of overweight/obese, especially in
children has increased over the last several decades. At present,
approximately 31.8% of US children aged 2-19 years are considered
overweight or obese.29 Among European countries, overweight/
obese in children below the age of ten ranges from more than 40%
in southern Europe to less than 10% in northern Europe.29 In Den-
mark, the combined prevalence of childhood overweight/obese is
10%-12%, in preschool children,30 increasing to 15%-22% during
adolescence.31 Given prevalence is based on age- and gender-speci-
fic BMI. However, definitions of overweight/obese and the refer-
ence populations differ between studies and countries.29
4.3 | Main therapeutic classes
In accordance with previous epidemiological studies, we found a high
use of respiratory drugs, for example, inhaled steroids and short-act-
ing beta-2 agonists 3 and drugs acting on the nervous system. In
group N, we found that both methylphenidate and antipsychotics
such as quetiapine and aripiprazole were highly prevalent. Of notice,
the use of antipsychotic agents is considered very problematic in this
population, due to side effects such as weight gain and metabolic
syndrome.32,33
4.4 | Using metrics of body size in children with
overweight/obesity
Although we found only one prescription had followed such a met-
ric, individualized dosing by metrics of body size may be more feasi-
ble in overweight/obese children than common pediatric dosing
strategies by TBW or fixed dose by age.5-10,16,17,19,20,23,34-38,38-46 A
reflection of the findings in this study, therefore, is that metrics of
body size does not seem to be implemented in the clinic unless they
have been “transformed” into clinical usefully guidelines. Conse-
quently, there is a risk of supra- or subtherapeutic doses. Alazmi
et al. estimated inappropriate drug dose prescriptions in 66% of the
overweight/obese children, in an outpatient pediatric clinic.47 How-
ever, general pediatric dosing guidelines, and maximum adult doses
were used as references, which is a limitation of the study. Without
studies of the individual drug in children who are overweight/obese,
it is not possible to decide, which dosing regimens are actually
appropriate. In line with this, the Pediatric Pharmacy Advocacy
Group recently came with a position statement recommending that
weight-based dosing should be used in patients ages <18 years who
are <40 kg and weight-based dosing should be used in patients
≥40 kg, unless the recommended adult dose for the specific indica-
tion is exceed.48 In this study, we found that the capping dose was
common practice, when the dose exceeded the maximum recom-
mended adult dose. This strategy seems pragmatic, but relies, how-
ever, on a precautionary approach rather than evidence, and may
not always be applicable. For example, carbamazepine, phenytoin,
digoxin, and propofol should be dosed more frequently and in higher
dose per kg body weight in normal weight children than in adults.17
On the other hand, there exists a well-known nonlinear relationship
between bodyweight and physiological factors such as clearance
(CL). Thus, providing maximum adult dose even though limited, may
result in supratherapeutic doses.5
4.5 | Strengths and limitations
A major strength of this study is that through manually review of
patient records, we were able to define the chosen dosage strategy
for each prescription, and included a long-term period of follow up.
Some obvious limitations are the retrospective design and the
method of chart audit with missing data and an underestimation of
drug prescription by GPs during follow up. Further, the pharmacody-
namics (PD) was not investigated in this study, and due to the retro-
spective nature of the study, we did not have valid or even the
necessary measurements ie visual analog scores (VAS) in accordance
to measure effects of analgesics.
5 | CONCLUSION
This study highlights the shortage of dosing guidelines in children,
who are overweight/obese. We found a large interindividual variabil-
ity in dosing regimens, even in drugs with narrow therapeutic inter-
vals. The clinicians rely on “best practice”, as evidence-based dosage
regimens are missing for many drugs prescribed during childhood.
5.1 | Perspective
Especially prospective, PK/PD and randomized studies of different
dosage strategies are needed to provide information on optimal dos-
ing in children, who are overweight/obese. Meanwhile we encourage
the associations of pediatricians in collaboration with clinical
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pharmacologists and other health care professionals, for example,
pediatric pharmacists to standardize dosage guidelines. Individualized
dosing strategies and PKPD modeling may be useful tools in this
population.
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